ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
ICU Medical (ICUI) will release its third quarter 2026 results and hold an earnings conference call on November 5, 2026. Results are scheduled for approximately 4:00 p.m. ET, followed by the call at 4:30 p.m. ET. A simultaneous webcast and a webcast replay will be available through the company's website.
ICU Medical (Nasdaq: ICUI) will participate in two upcoming investor conferences in September 2026. Management will attend the Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026, in Boston, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, in New York.
ICU Medical will hold fireside chats at both events and conduct one-on-one investor meetings. According to the company, live audio webcasts and archived replays of the discussions will be available via the Investors > Event Calendar section of its website.
ICU Medical (Nasdaq: ICUI) reported second quarter 2026 GAAP revenue of $551.7 million, up 1% year-over-year, with non-GAAP organic revenue up 6% excluding the IV Solutions divestiture and FX. GAAP gross profit rose to $235.1 million and gross margin improved to 43% from 38%.
GAAP net income was $19.1 million ($0.76 diluted EPS) versus $35.3 million ($1.43) a year earlier, while adjusted diluted EPS increased to $2.37 from $2.10 and adjusted EBITDA to $110.0 million from $100.3 million. For fiscal 2026, the company raised GAAP net income guidance to $73–$83 million and GAAP diluted EPS to $2.89–$3.29, and lifted adjusted EBITDA guidance to $415–$435 million and adjusted diluted EPS to $8.60–$9.00.
ICU Medical (Nasdaq: ICUI) will release its second quarter 2026 financial results on Thursday, August 6, 2026, at approximately 4:00 p.m. ET (1:00 p.m. PT), followed by an earnings conference call at 4:30 p.m. ET (1:30 p.m. PT), accessible via phone and webcast.
Otsuka ICU Medical LLC (Nasdaq: ICUI – joint venture partner) plans an over $500 million expansion of IV solutions manufacturing in Austin, Texas. The project includes a new 500,000-square-foot facility alongside upgrades to the existing 700,000-square-foot site.
The expansion targets stronger North American supply resiliency, fully automated manufacturing, and accelerated non-DEHP IV solutions development, supporting evolving legislation and long-term FDA strategies for supplemental overseas supply.
ICU Medical (Nasdaq: ICUI) reported first quarter 2026 results for the period ended March 31, 2026. GAAP revenue was $530.2M, down 12% year‑over‑year; non‑GAAP organic revenue excluding the May 1, 2025 IV Solutions divestiture and FX rose 1%.
GAAP gross profit was $206.2M and gross margin improved to 39% from 35%. GAAP net income was $30.1M ($1.20 diluted EPS) versus a prior‑year GAAP net loss of $(15.5)M. Adjusted diluted EPS was $1.97.
ICU Medical (Nasdaq: ICUI) will release first quarter 2026 results on May 7, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) the same day.
Investors can join by phone at 1-800-343-4136 with conference ID ICUMED or listen via webcast on the company's investor website; a replay will be available.
ICU Medical (Nasdaq: ICUI) announced management will participate in three investor conferences in March–April 2026: Raymond James on March 2, 2026 (presentation at 11:15 a.m. PT), KeyBanc Healthcare Forum on March 18, 2026 (fireside chat at 10:30 a.m. PT), and Needham on April 13, 2026 (presentation at 7:15 a.m. PT).
A live audio webcast and archived replays will be available via the company investor website at https://ir.icumed.com.
ICU Medical (Nasdaq:ICUI) reported Q4 2025 revenue of $540.7M versus $629.8M a year earlier; full-year 2025 revenue was $2,231.3M versus $2,382.0M. GAAP Q4 gross margin improved to 38% from 36% and GAAP Q4 net loss narrowed to $(15.7)M.
Adjusted Q4 EPS was $1.91 and adjusted EBITDA was $98.2M. For FY 2026 the company guides GAAP net income of $26M–$44M, adjusted EBITDA $400M–$430M, and adjusted EPS $7.75–$8.45. Vital Care declined after the May 1, 2025 IV Solutions disposal.
ICU Medical (Nasdaq: ICUI) announced the timing for its fourth quarter 2025 earnings release and conference call. Results will be released on Thursday, February 19, 2026 at ~4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.
The call is accessible by phone (800-274-8461, conference ID “ICUMED”) and by webcast via the company website under Investors; a replay will be available.